MolecuLight Secures $11.7 Million in Financing to Accelerate Global Expansion
MolecuLight's fluorescence imaging devices provide clinicians with real-time visualization of bacteria florescence in wounds, enabling earlier detection and quantification leading to more effective treatment resulting in improved wound healing. MolecuLight's wound bed assessment aligns perfectly with CTP outcomes: A study by Ai-Jalodi and colleagues demonstrates that when the device indicates a bacteria-free wound bed, there is a 100% probability of CTP integration1, vs a skin substitute alone. By empowering healthcare providers to make informed decisions at the point of care, MolecuLight is helping to improve patient outcomes and reduce healthcare costs. The new investment will fuel MolecuLight's expansion in the US,
"MolecuLight's innovative technology has the potential to significantly improve patient outcomes and offers compelling benefits for all healthcare system stakeholders," said
"We are pleased to invest in MolecuLight. We believe in MolecuLight's mission to transform wound care and with their innovative technology," said
"iGan is proud to continue supporting MolecuLight on their journey to transform the management of wound care," said
"This financing is a testament to MolecuLight's strong market position and the significant impact our technology is having on patient care," said
Tungsten Advisors served as the exclusive financial advisor to MolecuLight.
____________________________ |
1 Ai-Jalodi O, Sabo M, Patel K, Bullock N, Serena L, Breisinger K, Serena TE. Efficacy and safety of a porcine peritoneum-derived matrix in diabetic foot ulcer treatment: a pilot study. J Wound Care. 2021 |
About MolecuLight
MolecuLight is the leader in in point-of-care fluorescence imaging. Their innovative devices empower healthcare providers to quickly and accurately detect elevated levels of bacteria in wounds, surgical sites, and other injuries. This real-time visualization of bacteria that is linked to infection empowers clinicians to make informed treatment decisions. Early and accurate detection of bacteria leads to more targeted treatment plans. By optimizing treatment plans, MolecuLight technology helps to accelerate healing and reduce the risk of complications. The multi-modal device combines bacterial detection, wound measurement, and imaging capabilities into a single tool, streamlining workflows and improving documentation accuracy. Integrating seamlessly with electronic medical records, MolecuLight empowers clinicians to deliver the highest standard of care while optimizing their workflow. For more information, please visit www.moleculight.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculight-secures-11-7-million-in-financing-to-accelerate-global-expansion-302222755.html
SOURCE MolecuLight
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pure Strategies Introduces Extended Producer Responsibility (EPR) Value Index
- Craveworthy Brands to Open Several Concepts at Georgia Institute of Technology
- InventHelp Inventor Develops New Doorstop (SBT-2279)
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
S1Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share